Anti-restenosis stent coatings to be developed:
This article was originally published in Clinica
CV Therapeutics is to develop drug-containing polymer coatings for cardiology stents with the aim of cutting restenosis rates. CVT has developed a group of small molecule cell inhibitors, including its lead compound CVT-313, which the US company believes may treat the cell proliferation that causes cleared arteries to re-close.
You may also be interested in...
Following hot on the heels of its Rapidly Manufactured Ventilator Specification document, the UK’s regulator has issued another speedy regulatory permit for fast production of respiratory assist devices.
Which drug candidates represent hope, and which hype? The Scrip team examine the COVID-19 pipeline, lessons from China, and some long term impacts on the sector.
China insists there is no double standard and won’t tolerate any quality issues in its centralized procurement process.